Equity

Companies are increasingly using algorithms and artificial intelligence (AI) to analyze the massive amount of data they scoop up about us to decide what financi

The future of pharmaceutical investment lies in the convergence of ESG principles with a strong emphasis on positive social contribution, ethical AI, and innovative business models. Companies that successfully navigate this landscape will be well-positioned to lead the industry in both financial performance and societal impact.

DUBAI, AE / ACCESS Newswire / March 14, 2025 / As financial markets become increasingly unpredictable, investors are seeking more reliable, data-driven solutions to manage risk and optimize decision-making.

Ambarella (NASDAQ: AMBA) stock has been in red-hot form on the market since the second half of 2024, but its healthy rally came to an abrupt halt following the release of its fiscal 2025 fourth-quarter results (for the three months ended Jan.

In order to act ethically, and provide technology that is both beneficial and widely used, it's imperative that organizations take an ethics-first approach.

By proactively addressing biases, prioritizing transparency and advocating for fairness, we can create digital experiences that are not only innovative but also ethical.

As artificial intelligence and technology advance in daily life, AI is refining processes and turbocharging corporate growth. Although building AI solutions has many advantages, it also presents an equal number of cautionary factors.

Equinix, Inc. (NASDAQ:EQIX), a global leader in digital infrastructure with a market capitalization of $90.87 billion, finds itself at a critical juncture as it navigates the rapidly evolving landscape of cloud computing and artificial intelligence (AI).